[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Achieve Life Sciences Inc (ACHV)

Achieve Life Sciences Inc (ACHV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Achieve Life Sciences Approaches Its First Post-CRL Earnings With Resubmission Timeline in Focus

Achieve Life Sciences Inc (ACHV) is scheduled to report second-quarter 2026 earnings on August 13, 2026. With analysts expecting a loss of $0.19 per share—representing a 32% improvement from the prior-year quarter—investors will be watching closely to see if the biotech company can maintain the momentum from its surprise Q1 beat or if last quarter's disappointing miss signals renewed execution challenges. The stock has surged 37% above its 200-day moving average, but recent earnings volatility and an options market pricing a 14% move suggest this report could be a pivotal moment for the rally.

Achieve Life Sciences is a clinical-stage pharmaceutical company focused on developing...

Fundamentals

See More
  • Market Capitalization, $K 686,789
  • Shares Outstanding, K 102,659
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,650 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 2.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 33.76

Options Overview Details

View History
  • Implied Volatility 67.66% (-26.00%)
  • Historical Volatility 46.59%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 656.67% on 03/02/26
  • IV Low 67.66% on 08/13/26
  • Expected Move (DTE 8) 0.98 (13.61%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 328
  • Volume Avg (30-Day) 371
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 36,336
  • Open Int (30-Day) 36,220
  • Expected Range 6.20 to 8.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 3
  • High Estimate $-0.14
  • Low Estimate $-0.22
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) +32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.76 +26.13%
on 07/17/26
7.34 -0.95%
on 08/13/26
+1.16 (+19.10%)
since 07/13/26
3-Month
4.43 +64.00%
on 05/19/26
7.34 -0.95%
on 08/13/26
+1.30 (+21.90%)
since 05/13/26
52-Week
2.45 +195.93%
on 08/14/25
7.34 -0.95%
on 08/13/26
+4.72 (+186.02%)
since 08/13/25

Most Recent Stories

More News
Achieve Life Sciences Approaches Its First Post-CRL Earnings With Resubmission Timeline in Focus

Barchart Research What to Expect from ACHV Earnings ACHV Generated August 12, 2026 Current Price $6.69 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 6.69% Achieve Life Sciences Approaches...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Nears Regulatory Decision With Manufacturing Questions Unresolved

Barchart Research What to Expect from ACHV Earnings ACHV Generated August 5, 2026 Current Price $6.66 EPS Estimate $$-0.18 Consensus Rating Strong Buy Average Move 6.69% Achieve Life Sciences Nears Regulatory...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Joins Russell 2000® Index

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) --...

ACHV : 7.25 (+8.37%)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (“Achieve” or the “Company”) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...

MANE : 111.00 (+1.79%)
TARS : 68.88 (-1.62%)
ACHV : 7.25 (+8.37%)
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52...

ACHV : 7.25 (+8.37%)

Business Summary

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc.,...

See More

Key Turning Points

3rd Resistance Point 7.06
2nd Resistance Point 6.92
1st Resistance Point 6.80
Last Price 7.25
1st Support Level 6.54
2nd Support Level 6.40
3rd Support Level 6.28

See More

52-Week High 7.34
Last Price 7.25
Fibonacci 61.8% 5.47
Fibonacci 50% 4.89
Fibonacci 38.2% 4.32
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.